2021
Wet-dry-wet drug screen leads to the synthesis of TS1, a novel compound reversing lung fibrosis through inhibition of myofibroblast differentiation
Ring NAR, Volpe MC, Stepišnik T, Mamolo MG, Panov P, Kocev D, Vodret S, Fortuna S, Calabretti A, Rehman M, Colliva A, Marchesan P, Camparini L, Marcuzzo T, Bussani R, Scarabellotto S, Confalonieri M, Pham TX, Ligresti G, Caporarello N, Loffredo FS, Zampieri D, Džeroski S, Zacchigna S. Wet-dry-wet drug screen leads to the synthesis of TS1, a novel compound reversing lung fibrosis through inhibition of myofibroblast differentiation. Cell Death & Disease 2021, 13: 2. PMID: 34916483, PMCID: PMC8677786, DOI: 10.1038/s41419-021-04439-4.Peer-Reviewed Original ResearchConceptsAnti-fibrotic effectsDopamine receptor 3Lung fibrosisMyofibroblast activationReceptor 3Idiopathic pulmonary fibrosis patientsMyofibroblast differentiationPulmonary fibrosis patientsProgression of fibrosisTransforming Growth Factor-β PathwayGrowth factor β pathwayHigh-throughput screenDisease progressionMurine modelFibrosisFibrosis patientsFibrotic diseasesDrug screensLung fibroblastsNovel compoundsProgressionΒ pathwayImportant targetDopaminePrimary fibroblasts
2007
Corrigendum to “Coexpression of Notch1 and NF-κB signaling pathway components in human cervical cancer progression” [Gynecol. Oncol. 104 (2007) 352–361]
Ramdass B, Maliekal T, Lakshmi S, Rehman M, Rema P, Nair P, Mukherjee G, Reddy B, Krishna S, Pillai M. Corrigendum to “Coexpression of Notch1 and NF-κB signaling pathway components in human cervical cancer progression” [Gynecol. Oncol. 104 (2007) 352–361]. Gynecologic Oncology 2007, 106: 277. DOI: 10.1016/j.ygyno.2007.03.020.Peer-Reviewed Original Research